DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

and Biohaven’s next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus ...

ADC is considered a core technology for next-generation cancer drugs that selectively deliver drugs only to cancer cells. It consists of three connected elements: antibody, payload, and linker ...

Axcynsis is planning to initiate a Phase 1 multicentre clinical trial in the United States in 1Q 2025. AT03-65 is a differentiated ADC that selectively binds to CLDN6 with strong affinity. It is ...

(NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...